Vir Biotechnology, Inc. Announces 2024 Annual Meeting of Stockholders

Ticker: VIR · Form: DEF 14A · Filed: Apr 19, 2024 · CIK: 1706431

Vir Biotechnology, Inc. DEF 14A Filing Summary
FieldDetail
CompanyVir Biotechnology, Inc. (VIR)
Form TypeDEF 14A
Filed DateApr 19, 2024
Risk Levellow
Pages16
Reading Time19 min
Key Dollar Amounts$20,000
Sentimentneutral

Sentiment: neutral

Topics: Vir Biotechnology, Annual Meeting, Proxy Statement, Executive Compensation, Independent Auditor

TL;DR

<b>Vir Biotechnology, Inc. will hold its 2024 Annual Meeting of Stockholders on May 29, 2024, to elect directors, vote on executive compensation, and ratify auditors.</b>

AI Summary

Vir Biotechnology, Inc. (VIR) filed a Proxy Statement (DEF 14A) with the SEC on April 19, 2024. Annual Meeting scheduled for May 29, 2024, at 9:00 a.m. Pacific Time. Stockholders can attend virtually at www.virtualshareholdermeeting.com/VIR2024. Key agenda items include election of four director nominees, advisory vote on executive compensation, and ratification of Ernst & Young LLP as independent auditor. The record date for voting eligibility is April 1, 2024. The company is incorporated in Delaware and headquartered in San Francisco, CA.

Why It Matters

For investors and stakeholders tracking Vir Biotechnology, Inc., this filing contains several important signals. The election of directors and advisory vote on executive compensation are standard governance procedures that allow shareholders to influence company leadership and pay practices. Ratifying the independent auditor is crucial for maintaining financial transparency and investor confidence in the company's financial reporting.

Risk Assessment

Risk Level: low — Vir Biotechnology, Inc. shows low risk based on this filing. The filing is a routine proxy statement with no new financial or operational disclosures, indicating a stable, ongoing operational status.

Analyst Insight

Review the director nominees and executive compensation proposals to inform voting decisions at the Annual Meeting.

Key Numbers

  • 4 — Director Nominees (Number of director nominees to be elected at the Annual Meeting.)
  • 2027 — Director Term (Year until which the elected directors will hold office.)
  • 2024 — Fiscal Year End (The company's fiscal year ends on December 31, 2024.)
  • 16-digit — Control Number (Required for virtual attendance and online voting at the Annual Meeting.)

Key Players & Entities

  • Vir Biotechnology, Inc. (company) — Registrant and filer of the proxy statement.
  • Ernst & Young LLP (company) — Proposed independent registered public accounting firm.
  • May 29, 2024 (date) — Date of the Annual Meeting of Stockholders.
  • April 1, 2024 (date) — Record date for determining stockholders eligible to vote.
  • San Francisco, CA (location) — Company's business and mailing address.

FAQ

When did Vir Biotechnology, Inc. file this DEF 14A?

Vir Biotechnology, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 19, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Vir Biotechnology, Inc. (VIR).

Where can I read the original DEF 14A filing from Vir Biotechnology, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Vir Biotechnology, Inc..

What are the key takeaways from Vir Biotechnology, Inc.'s DEF 14A?

Vir Biotechnology, Inc. filed this DEF 14A on April 19, 2024. Key takeaways: Annual Meeting scheduled for May 29, 2024, at 9:00 a.m. Pacific Time.. Stockholders can attend virtually at www.virtualshareholdermeeting.com/VIR2024.. Key agenda items include election of four director nominees, advisory vote on executive compensation, and ratification of Ernst & Young LLP as independent auditor..

Is Vir Biotechnology, Inc. a risky investment based on this filing?

Based on this DEF 14A, Vir Biotechnology, Inc. presents a relatively low-risk profile. The filing is a routine proxy statement with no new financial or operational disclosures, indicating a stable, ongoing operational status.

What should investors do after reading Vir Biotechnology, Inc.'s DEF 14A?

Review the director nominees and executive compensation proposals to inform voting decisions at the Annual Meeting. The overall sentiment from this filing is neutral.

Risk Factors

  • Compliance with SEC Regulations [low — regulatory]: The company must comply with all SEC rules and regulations regarding proxy solicitations and annual meetings.
  • Conduct of Annual Meeting [low — operational]: Ensuring the virtual Annual Meeting runs smoothly and all stockholders can participate effectively.
  • Auditor Independence and Effectiveness [low — financial]: The effectiveness and independence of the appointed independent registered public accounting firm are critical for financial reporting integrity.

Key Dates

  • 2024-05-29: Annual Meeting of Stockholders — Key date for voting on corporate matters and electing directors.
  • 2024-04-01: Record Date — Determines which stockholders are eligible to vote at the Annual Meeting.

Glossary

Proxy Statement
A document filed with the SEC that provides shareholders with information about matters to be voted on at a company's annual meeting. (Provides essential details for shareholders to make informed voting decisions on director elections and other proposals.)
Independent Registered Public Accounting Firm
An external audit firm hired to examine a company's financial statements. (Ensures the accuracy and reliability of the company's financial reporting, which is vital for investor trust.)
Record Date
A specific date set by a company to determine which shareholders are eligible to receive dividends or vote at a shareholder meeting. (Defines the pool of eligible voters for the Annual Meeting.)

Filing Stats: 4,801 words · 19 min read · ~16 pages · Grade level 12.9 · Accepted 2024-04-19 08:32:38

Key Financial Figures

  • $20,000 — ods. We will pay a fee of approximately $20,000 to Innisfree M&A Incorporated plus cost

Filing Documents

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 26

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 29 TRANSACTIONS WITH RELATED PERSONS 66 HOUSEHOLDING OF PROXY MATERIALS 68 OTHER MATTERS 69 TABLE OF CONTENTS Proxy Statement Summary This summary highlights important information you will find in this proxy statement. As it is only a summary, please review the complete proxy statement before you vote. Annual Meeting Information DATE: Wednesday, May 29, 2024 TIME: 9:00 a.m. Pacific Time LOCATION: Online only at www.virtualshareholdermeeting.com/VIR2024 RECORD DATE: April 1, 2024 Voting Matters and Vote Recommendation Voting Matter Board Recommendation Page Number for more detail Proposal 1—Election of Directors FOR each nominee 7 Proposal 2—Advisory Vote on Executive Compensation FOR 23 Proposal 3—Ratification of Appointment of Independent Registered Public Accounting Firm FOR 24 Corporate Governance Matters We are committed to the highest standards of ethics, business integrity and corporate governance, which we believe will ensure that our Company is managed for the long-term benefit of our stockholders. Our governance practices are designed to establish and preserve the accountability of the Board of Directors and management, provide a structure that allows the Board to set objectives and monitor performance, ensure the efficient use of Company resources and enhance stockholder value. Please see "Information Regarding the Board of Directors and Corporate Governance" for more information. Our commitment to good corporate governance is illustrated by the following practices: Board independence (9 out of 11 directors are independent) Independent Board Chair Independent directors regularly meet in executive sessions without management or non-independent directors present 100% independent Audit, Compensation and Nominating and Corporate Governance Committees Board refreshment practices Annual Board and Committee self-assessments Strong corporate governance guidelines and policies Boa

Executive Compensation Matters

Executive Compensation Matters Proposal 2 – Advisory Vote on Executive Compensation The Board of Directors recommends that stockholders vote to approve, on an advisory basis, the compensation paid to the Company's named executive officers as described in this proxy statement (the "say-on-pay" vote). Detailed information about the compensation paid and awarded to our named executive officers can be found beginning on page 23 . ii TABLE OF CONTENTS Our executive compensation programs are designed to attract, motivate and retain our executive officers, who are critical to our success. Highlights of our executive compensation best practices follow. Recruited and onboarded several new executives, including our CEO: In 2023, we recruited several highly skilled leaders (including the CEO and two NEOs) to our executive management team and promoted others from within the Company. Enabled smooth transition of leadership without special severance arrangements: There were no special severance arrangements granted to any of the departing members of the executive management team in 2023. Strong pay-for-performance alignment: The majority of each named executive officer's pay is "at-risk" and is tied to corporate performance, whether through our annual incentive plan or through equity-based compensation. Additional disclosure throughout the CD&A: This year we expanded disclosure throughout the Compensation Discussion and Analysis to provide stockholders greater insight into how compensation decisions are made and the rationale behind them. Our Auditors Proposal 3 – Ratification of Appointment of Independent Registered Public Accounting Firm You are being asked to vote to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2024. Detailed information about this proposal can be found beginning on page 24 . YOUR VOTE IS IMPORTANT. Whether or not you plan to attend the Annual Meeting, we urge

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.